**Study Summary:** This study looks at different ways to use a medicine called *ibrutinib* for people with a type of blood cancer called **Chronic Lymphocytic Leukemia (CLL)**. *Ibrutinib* is sometimes mixed with another medicine, *venetoclax*. The study is trying to see if changing the dose of *ibrutinib* can help reduce side effects. **Chronic Lymphocytic Leukemia (CLL)** is a type of cancer that affects white blood cells. To join the study, you must have CLL or a similar condition called **Small Lymphocytic Lymphoma (SLL)**. You also need to be able to take care of yourself pretty well according to a scale called **ECOG Performance Status**. Women in the study must use birth control and agree not to get pregnant. Some conditions, like certain heart diseases or other blood problems, mean you can't join. **Key Points:** - **Length of Study:** Details on the duration are not provided, but participants must agree to follow all study rules. - **Visits Needed:** Participants will need to attend regular visits for check-ups and to get medicine. - **Compensation:** There may be compensation, although it is not specifically mentioned in the study details.

It's important to talk to your doctor to see if you qualify and if this study is right for you.